Previous 10 | Next 10 |
home / stock / pfe / pfe articles
Thursday, Immuneering Corporation (NASDAQ:IMRX) revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-...
Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization...
Pfizer Inc. (NYSE: PFE) shares closed slightly higher on Wednesday. The New York-based pharmaceutical giant recently said that the European Commis...
Tuesday, Pfizer Inc (NYSE:PFE) announced that a Phase 3 study of the antibody-drug conjugate Adcetris (brentuximab vedotin) combined with...
Pharmaceutical giant Pfizer Inc (NYSE:PFE) is redirecting its strategic focus from COVID to cancer drugs to bounce back from a tumul...
RBC Capital Markets upgraded REGENXBIO Inc (NASDAQ:RGNX), a company focused on developing gene therapies. Recently, REGENXBIO reported ad...
Retail traders have been observed to be selling off their shares in the ‘Magnificent Seven’ tech stocks, with a noticeable shift toward...
Wednesday, the FDA approved Pfizer Inc’s (NYSE:PFE) inotuzumab ozogamicin (Besponsa) for pediatric patients one year and older...
ViiV Healthcare, majority owned by GSK Plc (NYSE:GSK), with Pfizer Inc (NYSE:PFE) and Shionogi Limited as shareholder...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 06:28:00 ET Pfizer (NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess ...
2024-07-01 10:48:00 ET It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment opportunities is a lot more challenging than it was a year ago....
Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to and will join the Audit Committee and Compensation Committee of Pfizer’s Board. Mr. Taraporevala served as Presid...